AzTrials
AzTrials

Live Birth Delivery RateNCT00670059

Pre-Implantation Genetic Screening in Women Under the Age of 36 Years With Single Embryo Transfer

A study testing single embryo transfer without aneuploidy screening and single embryo transfer with aneuploidy screening in people with Live Birth Delivery Rate, run by Vrije Universiteit Brussel at 1 site in Belgium.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

BACKGROUND: Single-embryo transfer is a well-accepted strategy to avoid multiple pregnancies in an assisted reproductive technology programme. The selection of the embryo with the highest implantation potential is a crucial step. Read more about this study

Who is it for?
Ages 18 to 35 years, women only
Conditions the study is for
Live Birth Delivery Rate
What is being tested?
single embryo transfer without aneuploidy screening and single embryo transfer with aneuploidy screening
Could I receive a placebo?
No, everyone receives an active treatment
How many people
240 participants
Where
1 siteBelgium
Study dates
Oct 2004to Feb 2008
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 35 years
  • Women only
  • No healthy volunteers
  • Adult

Who may be able to join

  • ovulatory women undergoing infertility treatment
  • maternal age below 36 years
  • need for ICSI
  • motile sperm: more than 1x1000000 sperm cells/ml
  • both having a normal karyotype

Who cannot join

None listed.

Trial locations and contacts

1 site in 1 country.

Belgium1 site
  • Staessen C

    Brussels, Brussels Capital, 1090

Other trials in Belgium

About this study

Official title: Pre-Implantation Genetic Screening in Women Under the Age of 36 With Single-Embryo Transfer

BACKGROUND: Single-embryo transfer is a well-accepted strategy to avoid multiple pregnancies in an assisted reproductive technology programme. The selection of the embryo with the highest implantation potential is a crucial step. Besides the morphological quality and embryo kinetics up to the blastocyst stage, pre-implantation genetic screening (PGS) of aneuploidy has been advocated as an adjuvant approach by which to select the right embryo for transfer.

METHODS: Couples with a female partner younger than 36 years were randomly assigned to undergo transfer of a single blastocyst in a cycle with or without PGS using fluorescence in situ hybridization for the chromosomes X, Y, 13, 16, 18, 21 and 22.

Read the detailed description

Study design Between October 2004 and December 2006, ovulatory women undergoing infertility treatment were asked to participate in this RCT subject to the following inclusion criteria: maternal age below 36 years, need for ICSI and having motile sperm (sperm parameters: more than 1 x 106 sperm cells/ml) and both partners having a normal karyotype. Following written informed consent, eligible couples were randomly assigned to ICSI followed by blastocyst transfer either with or without PGS on the eight-cell stage embryo. Randomization was performed at the outpatient clinic, and each patient could be included only once. The consent form mentioned that patients allocated to PGS group would agree to donate embryos for research if these were chromosomally abnormal or unsuitable for transfer or cryopreservation. The study was approved by the Ethics Committee of the University Hospital. The patients were aware of the treatment allocation and were informed at the moment of transfer concerning the chromosomal abnormalities observed and about the morphological quality of the embryos.

Ovarian stimulation, oocyte retrieval and embryo culture Controlled ovarian hyperstimulation was carried out in an antagonist protocol using recombinant FSH combined with a GnRH antagonist (ganirelix, Orgalutran, NV Organon) (Kolibianakis et al., 2004) or an agonist protocol, using GnRH analogues for pituitary desensitisation (buserilin, Suprefact; Hoechst, Frankfurt, Germany), combined with human menopausal gonadotrophins (hMG)(Menopur, Ferring Pharmaceuticals A/S, Copenhagen, Denmark) or recombinant FSH (Puregon, NV Organon, Oss, The Netherlands)(Van de Velde et al., 1998). Final oocyte maturation was induced by the administration of 10,000 IU of HCG. Transvaginal ultrasound-guided oocyte retrieval was scheduled 36 h after HCG administration. ICSI was used to fertilize the oocytes. Sperm preparation, in vitro fertilization, intracytoplasmic sperm injection procedures and embryo culture were carried out as described by Van Landuyt et al. (2005).

Assessment of fertilization and embryo evaluation Fertilization was assessed as the number of 2PN zygotes per COC retrieved. Embryo evaluation was performed on days 2 and 3 by recording number of blastomeres and percentage of fragmentation. Grade A embryos were defined as embryos without anucleate fragments. Grade B embryos had blastomeres of equal or unequal sizes, with a maximum of 20 % of the volume of the embryo filled with anucleate fragments. In grade C embryos, anucleate fragments were present in 20-50 % of the volume of the embryo. Grade D embryos had more than 50% of the volume of the embryo filled with anucleate fragments. The embryos were evaluated daily until day 5. On day 5, the embryos were classified into arrested embryos showing no signs of compaction on day 5, compacting embryos (C1-C2), early blastocysts (Bl1-Bl2) and expanding blastocysts (Bl3-Bl7) according to the classification proposed by Gardner and Schoolcraft (1999). Embryos were considered for transfer at day 5 only from the compacting stage on. In both groups, supernumerary embryos were cryopreserved on day 5 or 6.

Embryo biopsy Embryos of grade A, B or C with at least five blastomeres were biopsied (Joris et al., 2003) in the morning of day 3 after ICSI. These selection criteria to decide whether an embryo was suitable for biopsy were the same as those used to decide whether an embryo was transferable on day 3 in the regular ICSI programme without PGD. Before biopsy of one blastomere, the blastomeres were checked for the presence of nuclei. If consequently no nuclear material was found during fixation, a second blastomere was removed. Embryo biopsy was carried out in HEPES-buffered medium under oil using laser technology (Fertilase) as was earlier described in detail (Staessen et al., 2004).

Spreading of the interphase nuclei and FISH procedure Using a mouth pipette, the individual blastomeres were first rinsed in medium and then transferred to a 1 µl droplet of 0.01 N HCl/ 0.1% Tween 20 solution (Coonen et al., 1994) on a Superfrost Plus glass slide (Kindler GmbH, Freiburg, Germany). A two-round FISH procedure was performed allowing us to detect the chromosomes X, Y, 13, 18, 21 (round 1) and 16, 22 (round 2) as was previously described in detail (Staessen et al., 2004).

FISH scoring criteria The specific FISH signals detected in a given blastomere were interpreted as follows: (i) a blastomere was considered to be diploid when the two gonosomes and two chromosome 13-, 16-, 18-, 21- and 22 specific signals were present; (ii) a blastomere was considered to be haploid, triploid or tetraploid when respectively one, three or four signals for the investigated chromosomes were present; (iii) a blastomere was considered to be aneuploid when an extra (trisomic) or missing (monosomic) signal for one chromosome was observed, in the presence of two signals for the remaining chromosomes analysed; (iv) a blastomere was considered as combined abnormal when it was neither diploid nor haploid, triploid, tetraploid or aneuploid. After FISH analysis, only embryos found to be chromosomally normal in the corresponding biopsied blastomere were transferred on day 5. FISH analysis was performed by experienced cytogeneticists trained in cytogenetics and FISH analysis. The results of the first and second round were analysed by two observers using a Zeiss Axioplan 2 fluorescence microscope.

Embryo transfer In the PGS group the transfer was performed on day 5 if at least one compacting embryo or early blastocyst was obtained from the embryos found to be genetically normal. In the control group the transfer was also performed if at least one compacting embryo or early blastocyst was obtained on day 5; 4 embryo transfers were performed on day 3.

Pregnancy A biochemical pregnancy was defined as two consecutive positive rising (> 15IU/ml) serum hCG levels. A preclinical miscarriage was defined as two consecutive positive rising (> 15IU/ml) serum hCG levels, but no FHB at least 6 weeks post embryo transfer. A clinical pregnancy was defined as an intrauterine gestational sac with positive foetal heart activity seen at ultrasonography performed at least 6 weeks post-embryo transfer. A miscarriage was defined as a pregnancy loss before 20 weeks of gestation. The live birth delivery rate was defined as the number of live birth deliveries expressed per 100 initiated cycles, aspiration cycles or embryo transfer cycles (Zeghers-Hochschild et al., 2006).

Endpoint The primary outcome was live birth delivery rate. Statistical analysis Analysis was performed according to the intention to treat. For descriptive statistics, we used means±SD. Continuous variables were analyzed by the t-test for independent samples. Categorical variables were analyzed by chi-square test. All tests were two-sided, and a P value of less than 0.05 was considered to indicate statistical significance. Using group sequential methods, we calculated that the enrolment of 447 patients in each group would give the study a statistical power of 80% to detect an absolute difference of 10% in the delivery rate between the groups at an alpha level of 0.05 with the use of a two-sided z-test.

Being tested
single embryo transfer without aneuploidy screening, single embryo transfer with aneuploidy screening
Keywords
Single embryo transfer/ aneuploidy screening

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • single embryo transfer without aneuploidy screeningGenetic

    without aneuploidy testing for the chromosomes XY, 13, 16, 18, 21, 22

  • single embryo transfer with aneuploidy screeningGenetic

    with aneuploidy testing for the chromosomes XY, 13, 16, 18, 21, 22

Study groups in NCT00670059
Study groupRoleWhat they receive
AActive comparatorgroup: single embryo transfer without aneuploidy screening
Receives: Genetic: single embryo transfer without aneuploidy screening
BExperimentalgroup: single embryo transfer with aneuploidy screening
Receives: Genetic: single embryo transfer with aneuploidy screening

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. live born delivery rate

    Measured: at birth of the child

Secondary outcomes (1)
  1. Number of pregnancies obtained with or without pre-implantation genetic screening

    Measured: positive HCG

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 May 2008 (estimated)
  2. Study startOct 2004
  3. Primary completionJun 2007
  4. Study completionFeb 2008

Why it stopped: At the first prespecified interim analysis

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
240 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00670059
Sponsor's protocol ID
SET study
Status last verified
Apr 2008
First submitted
29 Apr 2008
Last updated
1 May 2008
Results posted
No
Data monitoring committee
No

Publications

  • Staessen C, Platteau P, Van Assche E, Michiels A, Tournaye H, Camus M, Devroey P, Liebaers I, Van Steirteghem A. Comparison of blastocyst transfer with or without preimplantation genetic diagnosis for aneuploidy screening in couples with advanced maternal age: a prospective randomized controlled trial. Hum Reprod. 2004 Dec;19(12):2849-58. doi: 10.1093/humrep/deh536. Epub 2004 Oct 7.

    PubMed 15471934
  • Staessen C, Verpoest W, Donoso P, Haentjens P, Van der Elst J, Liebaers I, Devroey P. Preimplantation genetic screening does not improve delivery rate in women under the age of 36 following single-embryo transfer. Hum Reprod. 2008 Dec;23(12):2818-25. doi: 10.1093/humrep/den367. Epub 2008 Oct 17.

    PubMed 18930977

Questions about this trial

What is this clinical trial studying?

A study testing single embryo transfer without aneuploidy screening and single embryo transfer with aneuploidy screening in people with Live Birth Delivery Rate, run by Vrije Universiteit Brussel at 1 site in Belgium.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 1 May 2008. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: At the first prespecified interim analysis). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

live born delivery rate (time frame: at birth of the child). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00670059, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 May 2008.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in